85 results about "Spironolactone" patented technology

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and / or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

Disclosed herein is a pharmaceutical composition, comprising: (a) spironolactone; (b) a xanthan gum; (c) an anti-foaming agent; (d) a preservative; (f) a dispersing agent; (g) a sweetening agent; (h) a flavoring agent; (i) optionally a buffer to maintain the pH of the pharmaceutical composition within a range described herein; and (j) a sufficient amount of a water vehicle.

Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.

The invention discloses an antihypertensive medicine synergist. The antihypertensive medicine synergist is composed of the medicine constituents in the following parts by mass: 0.5-15 parts of spirolactone and 0.25-13 parts of hydrochlorothiazide. The synergist disclosed by the invention is capable of creating a high-potassium low-sodium antihypertensive internal environment with moderate serum. The synergist is capable of increasing the pressure-reducing standard-reaching rate of an antihypertensive medicine and improving the stability and safety of the pressure-reducing effect of the antihypertensive medicine, stable in curative effect, few in adverse reactions and high in patient compliance.

The invention discloses a method for preparing spirolactone. The method comprises the following steps: 1, performing a reaction on a compound shown as a formula (II) and acrolein under the action of a catalyst, alkali and Lewis acid to obtain a compound shown as a formula (III); 2, performing a reaction on the compound shown as the formula (III) and chloranil to obtain a compound shown as a formula (IV); 3, performing an addition reaction on the compound shown as the formula (IV) and thioacetic acid to obtain the spirolactone. The preparation method of the spirolactone, provided by the invention, has the advantages of a short synthetic route, cheapness and easy obtainment of used reagents, simple operation, high total yield rate, and suitability for industrial production; a novel way for preparing the spirolactone is provided.

The invention relates to methods, compositions, and kits for the treatment of proteinuria and / or hypertension (e.g., proteinuria and / or hypertension arising from primary renal disease (e.g., focal segmental glomerulosclerosis, glomerular disease) or secondary to other conditions (e.g., diabetes, diabetic nephropathy, liver disease). Specifically, the invention relates to methods involving combination therapy wherein an indoline (e.g., indapamide) is administered in combination with an anti-aldosterone agent (e.g., spironolactone and / or epleronone).

The invention discloses a cosmetic which can balance oil secreting, resist sunlight and skin aging and essentially consists of rennin, honey, titanium dioxide, carbocisteine, niacin amide, vitamin E, vitamin F, cod liver oil, spironolactone and substrate cream, which are prepared according to certain weight proportion and function coordinately to achieve the effect of whitening and skincare. The invention has the triple effects including skincare, sun block and aging resistance. Firstly, the cosmetics regulates the metabolism of skin oil secretion to balance the secretion of the oil secretion, smoothen pores and reduce the occurrence rate of acne; secondly, the product effectively prevents people from being hurt by ultraviolet and reduces the settlement of melanin, thereby having good sunblock and whitening effects; finally, the product slows down the aging of skin, smoothens the skin and provides delicate and fair skin to users. The invention has scientific components, simple fabrication and unique treatment effect and is suitable for large-batch production.